Company intelligence / Profile preview

GlycoMimetics

Rockville, Maryland, United Statesglycomimetics.com ↗

Ownership: Public · GLYC
Employees: ~80
Development stage: Phase 3

Overview

The company's lead molecule uproleselan did not meet the primary endpoint in the National Cancer Institute Phase 2/3 study as announced on October 29, 2024. The FDA determined that an additional clinical trial would be required for the regulatory path forward for uproleselan in relapsed and refractory AML.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Small molecule drugs (glycomimetics)
Industry: Biotech

Drug pipeline

2 assets

uproleselan

Phase 3

Indications: Acute myeloid leukemia

1 more asset in the full pipeline.

Partnerships

National Cancer Institute (NCI)Alliance for Clinical Trials in Oncology

Beyond the preview

Go deeper on GlycoMimetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoMimetics.